Janux Therapeutics Inc. (NASDAQ: JANX) is One of the best cancer stocks to invest in now. On February 17, Janux Therapeutics Inc. (NASDAQ: JANX) has initiated patient dosing in the Phase 1 study of JANX011. The company has already dosed the first patient in an evaluation trial of JANX011 for the treatment of autoimmune diseases.
Pixabay/Public Domain
The candidate drugs are designed to induce deep and lasting immune reconstitution by targeting the depletion of CD19-expressing B cells in the blood and tissues. Designed on the company’s ARM platform, it aims to deliver sustained target B-cell depletion. The drug has already shown potential to achieve pharmacodynamic effects comparable to CAR-T therapy.
“Dosing the first participant with JANX011 marks an important milestone for Janx and the first clinical evaluation of our ARM platform,” said David Campbell, Ph.D., President and CEO, Janx Therapeutics. “While JANX011 is initially being developed for autoimmune diseases, the distinct immune profile of the ARM platform may have broader implications in CD19-expressing diseases, including hematologic malignancies.”
Janux Therapeutics, Inc. (NASDAQ: JANX) is a clinical-stage biopharmaceutical company developing novel, tumor-active immunotherapies for the treatment of cancer while minimizing toxicity by maximizing T-cell targeting. Using its proprietary TRACTr, TRACIr, and ARM platforms, Janux engineers bispecific molecules that preferentially activate the immune response against solid tumors.
While we acknowledge the potential of JANX as an investment, we believe that some AI stocks offer higher potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: 13 Best Manufacturing Stocks to Invest Now and 11 AI Stocks That Are Going to the Moon.
Disclosure: None. Follow the inside port on Google News.
